Etubics Corporation Partners with the National Cancer Institute to Further Develop Therapeutic Cancer Vaccines
SEATTLE – (June 23, 2015) - Etubics Corporation , a privately held clinical stage biotechnology company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the National Institutes of Health (NIH). The parties will work together to further develop the Etubics Platform, which is employed to develop novel immunotherapeutic product candidates to treat cancer. Under the CRADA, the NCI and Etubics will collaborate on the preclinical and clinical development of a multi-